Editas Medicine, Inc. (NASDAQ:EDIT)

Lloyd Doyle
August 19, 2017

Oppenheimer Holdings now has a "Market Perform" rating on the stock. Earnings, with 5 analysts believing the company would generate an Average Estimate of $-0.6.

EDIT has been the topic of several recent research reports. Manufacturers Life Insurance Company, The downsized its position by shedding 386 shares a decrease of 13.6% from 03/31/2017 to 06/30/2017. They issued a "hold" rating and a $17.00 price objective on the stock.

Editas Medicine Inc.'s average Free Cash Flow per Share Growth Rate was 0 percent during the past 12 months.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 2.14, and a price to sales ratio of 1.82. Cann reaffirmed a "hold" rating on shares of Editas Medicine in a research note on Thursday, August 10th. They help determine the company's ability to continue operating. Five analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Editas Medicine presently has an average rating of "Buy" and a consensus price target of $26.03.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by BBNS and is the property of of BBNS. If you are reading this piece on another site, it was illegally stolen and republished in violation of US and global trademark & copyright laws. (NASDAQ:EDIT). Gerald Frank Cox, Chief Medical Officer reported the purchase of 4,000 shares of (EDIT). Market capitalization is the total value of any firm in the stock market. Editas Medicine has a 1-year low of $12.43 and a 1-year high of $29.20. The firm's 50-day moving average is $17.52 and its 200 day moving average is $19.10.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings data on Monday, May 15th.

Maximum and minimum EPS estimate for the current quarter is projected at $-0.48 and $-0.75, respectively, according to 5 analysts. Editas Medicine had a negative return on equity of 63.29% and a negative net margin of 1,864.00%. To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road.

In other Editas Medicine news, Director Kevin Bitterman sold 1,000,000 shares of the business's stock in a transaction on Monday, May 22nd. Manufacturers Life Insurance Company, The now holds 2,447 shares with a value of $41,000. The transaction related to this sale was declared in a document with the securities and exchange commission, which is available at this link. The stock closing price is now trading upward to its 50 day moving average with change of 21.71%, escalated to its 20 day moving average with figure of 18.63% and above its 200 day moving average with value 13.52%. Bank of America Corp DE now owns 5,936 shares of the company's stock worth $133,000 after buying an additional 2,489 shares during the last quarter.

In the market the company is trading down by -9.35% since yesterday's close of $20.74.

The company is expected to report earnings of $-0.6 a share for the next quarter. Bank of America Corp DE boosted its stake in Editas Medicine by 72.2% in the first quarter. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/bessemer-group-inc-acquires-shares-of-43636-editas-medicine-inc-edit/1488924.html. The firm has a Return on Assets (ROA) value of -38.20%. Barrett Asset Management LLC purchased a new stake in Editas Medicine during the first quarter valued at $223,000. Schwab Charles Investment Management Inc. now owns 42,150 shares of the company's stock worth $941,000 after buying an additional 3,249 shares during the period. Finally, Wells Fargo & Company MN increased its stake in Editas Medicine by 31.0% in the first quarter. Vanguard Group increased its position in Editas Medicine by 47.0% in the Q1. The Company is involved in treating patients with genetically defined diseases by correcting their disease-causing genes.

Other reports by Iphone Fresh

Discuss This Article